Through gene therapy, researchers engineered blood-forming stem cells (hematopoietic stem/progenitor cells, or HSPCs) to carry chimeric antigen receptor (CAR) genes to make cells that can detect and destroy HIV-infected cells. These engineered cells not only destroyed the infected cells, they persisted for more than two years, suggesting the potential to create long-term immunity from the virus that causes AIDS.
Antiviral drugs can suppress the amount of HIV in the body to nearly undetectable levels, but only an effective immune response can eradicate the virus. Researchers have been seeking a way to improve the body’s ability to combat the virus by engineering blood-forming stem cells to specifically target and kill HIV-infected cells for the life of the individual. Although chimeric antigen receptor (CAR) T-cells have emerged as a powerful immunotherapy for various forms of cancer – and show promise in treating HIV-1 infection – the therapy may not impart long-lasting immunity. Researchers, physicians and patients need T cell-based products that can respond to malignant or infected cells that may reappear months or years after treatment.
Because HIV uses CD4 to infect cells, the researchers used a CAR molecule that hijacks the essential interaction between HIV and the cell surface molecule CD4 to make stem cell-derived T-cells target infected cells. When the CD4 on the CAR molecule binds to HIV, other regions of the CAR molecule signal the cell to become activated and kill the HIV infected cell. The researchers found that, in test animals, modification of the blood-forming stem cells resulted in more than two years of stable production of CAR-expressing cells without any adverse effects. In addition, these cells were widely distributed throughout the lymphoid tissues and gastrointestinal tract, which are major anatomic sites for HIV replication and persistence in infected people. Most important, engineered CAR T-cells showed efficacy in attacking and killing HIV-infected cells.
These findings are the first to show that blood-forming stem cells can be modified with a CAR therapy that can safely engraft in the bone marrow, mature and become functional immune cells throughout the body. This could lead to the development of an approach allowing for safe, lifelong immunity to HIV. Such an approach is likely to work best when performed in combination with other treatment strategies, such as antiretroviral therapy. Researchers hope that this type of therapy could reduce infected individuals’ dependence on antiviral medications, lower the cost of therapy, and permit the possible eradication of HIV from its hiding places in the body. The approach also has potential against other infections or malignancies.
The Latest on: HIV gene therapy
- Global Gene Therapy Market is expected to witness a CAGR of 18.7%on October 8, 2019 at 7:55 am
While gene therapy was originally targeted for inherited disease, it is now capable of treating a variety of acquired problems including cancer and HIV. Initially delivered through viruses, now there ...
- Gene Therapy Market In-Depth Analysis 2019 :: Leading Key Players, Size, Shareon October 3, 2019 at 10:54 pm
Gene therapy is a widely used technique for the study by researchers in order to develop treatment of various diseases such as HIV, Cancer, Parkinson’s disease, hemophilia and even immune deficiencies ...
- A Phase I Study of Chemotherapy and Stem Cell Gene Therapy for People with HIV Who Developed Lymphomaon September 28, 2019 at 6:04 am
A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells (AMC 097) This study is for people who are HIV-positive, have lymphoma that persists ...
- Global & US Gene Therapy Market 2019-2020: Immunodeficiency Syndromes - The Focus of Gene Therapyon September 20, 2019 at 9:20 am
12.9 uniQure N.V. 12.10 Human Stem Cells Institute 12.11 Shanghai Sunway Biotech Co. Ltd. 12.12 Sibiono GeneTech Co. Ltd. For more information about this report visit ...
- Global & US Gene Therapy Market 2019-2020: Immunodeficiency Syndromes - The Focus of Gene Therapyon September 20, 2019 at 9:16 am
12.9 uniQure N.V. 12.10 Human Stem Cells Institute 12.11 Shanghai Sunway Biotech Co. Ltd. 12.12 Sibiono GeneTech Co. Ltd.
- Alabama man free of sickle cell after gene therapyon September 17, 2019 at 11:45 am
Researchers are hoping they have found a cure for sickle cell patients as gene therapy has rendered an Alabama man free ... The modified gene is then put back in using deactivated HIV. People who ...
- Alabama Man Free of Sickle Cell After Gene Therapyon September 17, 2019 at 7:54 am
The modified gene is then put back in using deactivated HIV. The trial is sponsored by biotech company ... Correction: An earlier version of the story said the gene therapy trial was sponsored by NIH.
- Gene Therapy Market Set to Achieve Higher Revenues and Analysis 2018 - 2026on September 10, 2019 at 11:52 pm
All over the world, gene therapy is being extensively studied by the researchers for the treatment of various diseases such as HIV, Cancer, Parkinson's disease, hemophilia and even immune deficiencies ...
- Global & US Gene Therapy Market Outlook to 2020 - Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nationson September 3, 2019 at 5:00 pm
Various researches are being performed across the globe to explore the potential of gene therapy for the treatment of incurable diseases, such as diabetes, cancer, and HIV amongst others. According to ...
- HIV Suppression Using Adenovirus-Mediated Gene Therapyon August 26, 2019 at 6:03 am
While a cure to HIV is thus still not reached, the adenoviral gene therapy promises a path to improve the management of HIV infections by keeping the viral concentrations low, thus managing disease ...
via Google News and Bing News